Better Than Botox: New Drug Set to Be a Blockbuster

Three beautiful women with a problem…

You know who these women are, don’t you?

Brooke Shields, 49. Brooke Shields played the teen beauty in the movie The Blue LagoonThe Blue Lagoon launched Shields’ career as a movie superstar.

Sarah Jessica Parker, 49. Sarah Jessica Parker played the role of Carrie Bradshaw, the cute, perky bombshell in the Sex and the City TV series.

Jennifer Aniston, 45. She played the role of Rachel Karen Green in the blockbuster hit TV series Friends.

What problem do these three women share?

You know what all these three beautiful women share? Beyond being women, or superstars?

Can’t guess? OK, I’ll give you a clue.

Go look at a picture of them on your computer right now.

Don’t see it? I’ll give you another clue.

All three are their mid- to late-40s now.

Give up?

The thing that all these women share is a problem that affects you and virtually every person who is in their mid to late-40s or older.

I’m talking about crow’s-feet.

If you’re 40 or older, you almost certainly have crow’s-feet. But you don’t have to be 40 to get crow’s-feet. Crow’s-feet begin to form when you hit your mid-20s, especially if you were tanning yourself or took poor care of your skin.

Your Face Is a Rubber Band

You see, the skin on our face is like a rubber band. What happens is that your body is not producing enough collagen and elastin. Collagen and elastin are proteins. And these two proteins are responsible for your skin’s elasticity. As you get older, your body produces less and less collagen and elastin. Next thing you know, you’ve got crow’s-feet.

Never smile, laugh, frown, squint or yawn…

So what should you do? Should you never smile or laugh or frown or yawn again?

Or perhaps you should never go out in the sun. Because as you know, being in the sun is another reason why we get crow’s-feet.

You see, if you want to lead a normal life, there’s simply no way to avoid getting crow’s-feet.

And that’s a good thing for the stock I want you to buy this week.

$28,616 for Scam Treatments

Right now, there’s no way to get rid of your crow’s-feet. The only thing you can do is buy incredibly expensive creams that claim to help. I looked these creams up at DermStore.com for you. Just so you know, DermStore is a leading online retailer of these creams.

One cream is selling for $511 for a year’s supply. Assume you start using this cream at age 25. And let’s also assume you’ll live till 81 (81 is the average life expectancy of a woman in the United States today). If you use those assumptions, you’ll spend $28,616 on this cream over your lifetime — not accounting for inflation. These creams have zero evidence to show that they actually work. But their marketing works great. Transparency Market Research estimates that we spent $122.3 billion on these kinds of anti-aging products in 2013.

117,233,218 potential customers.

I’m not a sexist, but let’s admit it: You know that your wife would love… love to get those crow’s-feet off her face. And that’s true for your mom or your sister as well. That means any product that can get rid of crow’s-feet has a gigantic market waiting for it, because as I’ve shown you, every person over 25 is a potential customer. But the truth is that women are the big spenders in this market.

How huge, how gigantic?

About 51.8%, or 160,593,450, of the U.S. population are women. Also, 73% of the population is over 25. That means that you have a potential market of 117,233,218 people that have crow’s-feet.

A drug that removes crow’s-feet is going to be huge.

You don’t have to be genius to see that a drug that can get those crow’s-feet off your wife’s or sister’s or mom’s face is going to be worth billions. Yes, billions. Why?

You go and do the math, just based on what women are willing to pay for those useless creams: $511 for a one-year supply. Imagine if a company sold an ointment that actually worked. How much would you be able to charge for that? Just common sense tells you that it would need to be a lot more than $511.

We can also look at a drug called Botox. Botox is an injectable drug that can remove the wrinkles on your forehead. Botox costs about $800. Each Botox treatment lasts about four months, which means you are spending $2,400 per year. And Botox had sales of nearly $2 billion in 2013.

Right now, I’m following a company that uses a cream to remove crow’s-feet.

It uses botulinum toxin too to treat these wrinkles.

Just so you understand, a toxin is something that can cause you harm. And botulinum toxin are bacteria that in high doses cause a disease called botulism. Most times, people who get botulinum toxin get it through contaminated food. And if you do get botulinum toxin, it can cause paralysis and muscle weakness. At very, very high doses, botulinum toxin can even kill you.

This new cream has just a tiny amount of botulinum toxin in it.

Beyond that, you should know that using botulinum toxin in injectable form is already approved by the FDA through Botox. Yes, that same Botox drug that I mentioned to you before, the one that had $2 billion in sales in 2013. The thing I want you to understand is this: The FDA already believes that using botulinum toxin is safe. And they have already approved an injectable version of this to treat wrinkles on your forehead, which are also called crow’s-feet.

I know what you’re thinking about now: Whoa, Paul, if Botox is already FDA approved for crow’s-feet, why are you recommending a stock that is just copying Botox? Why should I invest in an ointment version of Botox? And why would anyone want to use it?

Ointment vs. Injection

What would you prefer for your crow’s-feet? A needle injection to the corner of your eye? Or an ointment? Maybe some of you would prefer a poke. But I have no trouble telling you that I don’t like needles. From the time I was a little kid, I’ve always closed my eyes when I got poked. Even now, I look away when I get a poke. Expert studies show that as many as 20% of people don’t like needles. And I believe that even people that don’t mind needles are going to prefer an ointment if it is an available option.

An ointment solution to Botox could turn out to be the next blockbuster drug. Remember that a blockbuster is a drug that can generate $1 billion in sales.

Why? Because crow’s-feet is something we all are going to get. And that means lots of potential customers.

Second, the drug is certain to be used by people who hate getting wrinkles. This too means lots of potential customers.

Last, we know that people spend tons of money for these kinds of products. How? Global Industry Analysts, an elite research firm that charges thousands of dollars for its reports, estimates that by 2015 the anti-aging market is going to generate $291.9 billion in sales.

Yes, billion.

I expect the creators of this new anti-crow’s feet treatment will see their stock rise by 45% in 2015.

That’s because the stock I’m watching is mispriced right now.

As Thompson Clark, editor of Agora Financial’s Microcap Millionaires research advisory, tells us:

“The further along a drug is in getting FDA approval, the more it should be worth. There are four phases in approval, and a Phase 3 or 4 drug should be worth a lot of money. That’s because once a drug reaches Phase 3 status, approval is almost guaranteed. But every now and then, we see Phase 2 and 3 drugs at Phase 1 prices.”

The stock markets just not giving the company I’m watching credit for the huge potential of their crow’s-feet ointment.

By the time it completes its Phase 3 trials, the stock will be up 45%.

Now, it’s always possible for a clinical trial to bomb. Or the FDA can always come up with some reason to reject a drug. But I have to tell you that my research is showing this is a safe drug that works. And as I told you earlier, the medicine in this drug is the same as in Botox, an FDA-approved drug.

Don’t wait to invest in the latest in Botox treatments.

Get in today while this stock is still mispriced.

Regards,

Paul Mampilly
for The Daily Reckoning

Ed. Note: In today’s email edition of Tomorrow in Review, readers got an exclusive look at Paul’s stock recommendations in the biotech sector. Some of the companies he referred to were up 500% since he recommended them. Sign up for Tomorrow in Review today for FREE and don’t miss out on investment opportunities that will make you rich.

The Daily Reckoning